BioSpace News Archive

TransThera Sciences (Nanjing) Inc. today announces to deliver two oral presentations of tinengotinib clinical data in cholangiocarcinoma (CCA) at 2023 European Society for Medical Oncology (ESMO) Congress, and in breast cancer at 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting respectively.

CuraSen Therapeutics, Inc. announced that it has received a strategic investment of up to $5.8 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”) today announced that Dan Yerace, Director and Vice President of Operations, will participate in a panel titled, “Ambitious Innovation: Emerging Cell and Gene Therapies,” at the BioFlorida Conference on Thursday October 12th from 11:50 AM-12:50 PM.

Oct. 9, 2023 at their annual general meeting, the National Academy of Medicine announced the election of Hongkui Zeng, Ph.D, Allen Institute’s Executive Vice President and Director of the Allen Institute for Brain Science, to their membership for her leading role in understanding the cell types and the functional architecture of the mammalian brain.

Acousia Therapeutics received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ACOU085 in patients with cisplatin-induced hearing loss.

John D. Carpten, Ph.D., chief scientific officer at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, was presented with one of the highest honors in health and medicine when he was elected to the National Academy of Medicine.

MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for an antibody drug conjugate (ADC) that shows great promise to mitigate solid tumor cancer with an innovative approach to teamwork.

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery

BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the ROTH MKM Healthcare Opportunities Conference.   

Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA.